Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, in New York.

Rhea-AI Summary

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, in New York.

CEO Laxminarayan Bhat will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" at 8:00 AM ET and will be available for one-on-one meetings with investors throughout the day.

Argus Oct 2 session

+35.12% close to close Open Argus

Details

News Market Reaction – RVPH

On Oct 2, the day this news came out, RVPH closed 35.12% above the previous close.

Data tracked by StockTitan Argus for the Oct 2 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4^th Annual Roth Healthcare Opportunities Conference, being held on October 9, 2025, in New York, NY.

Roth Healthcare Opportunities Conference
Format: Panel discussion and one-on-one meetings
Panel Title: “Small Firms Tackling Blockbuster Indications”
Date: Thursday, October 9, 2025
Time: 8:00 AM ET

To learn more and submit a registration request, click here. Reviva’s management team will be available for one-on-one investor meetings on October 9, 2025.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Reviva Pharmaceuticals (RVPH) presenting at the Roth Healthcare Conference 2025?

Reviva's CEO will participate in a panel discussion on Thursday, October 9, 2025, at 8:00 AM ET in New York, NY.

What panel will RVPH's CEO participate in at the Roth Conference?

CEO Laxminarayan Bhat will participate in a panel titled 'Small Firms Tackling Blockbuster Indications'.

Will RVPH management be available for investor meetings at the Roth Conference?

Yes, Reviva's management team will be available for one-on-one investor meetings on October 9, 2025.

What therapeutic areas does Reviva Pharmaceuticals focus on?

Reviva is developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases.